Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft tissue infections, streptococcal pharyngitis and Helicobacter pylori eradication in adults.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulated quality‑assured batches for clinical use. The company adheres to EU GMP standards and offers reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Clarithromycin is a macrolide antibiotic used to treat infections of the respiratory and related systems.

Community‑acquired pneumonia: eliminates the causative bacteria and improves respiratory function. Acute bacterial sinusitis: reduces sinus inflammation and clears the infection. Skin and soft tissue infections: resolves bacterial skin infections and promotes healing. Streptococcal pharyngitis: eradicates streptococcal bacteria causing sore throat. Helicobacter pylori eradication: part of combination therapy to eradicate H. pylori infection.

Clarithromycin may cause a range of adverse reactions, from mild gastrointestinal symptoms to rare serious events.

Common Side Effects: - Nausea: mild gastrointestinal upset that may occur during therapy. - Diarrhea: loose stools, sometimes leading to dehydration. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered taste perception, often described as metallic.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - QT prolongation: cardiac rhythm disturbance that can precipitate arrhythmias. - Severe allergic reaction: anaphylaxis, rash, or angioedema demanding immediate medical attention.

When prescribing clarithromycin, clinicians should observe several safety precautions. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: use caution in patients with liver disease and monitor liver enzymes. - Cardiac risk: avoid in patients with known QT prolongation or who are taking other QT‑prolonging drugs. - Drug interactions: review concomitant medications for potential CYP3A4 inhibition or induction. - Pregnancy: category B; prescribe only when benefit outweighs potential risk to the fetus. - Store at ambient temperature: keep in original container, protect from light and moisture.

Clarithromycin interacts with several medicines through enzyme inhibition and other mechanisms.

Major Interactions (Avoid): - Simvastatin: increased risk of myopathy and rhabdomyolysis due to elevated statin levels. - Pimozide: elevated plasma concentrations can cause severe cardiac toxicity. - Carbamazepine: reduced efficacy as clarithromycin induces its metabolism.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect; monitor INR closely. - Digoxin: increased serum concentration; monitor cardiac levels. - Oral contraceptives: reduced effectiveness; advise alternative contraception methods.